Abstract Background Standardised quality indicators have been proposed to benchmark inflammatory bowel disease (IBD) care across centres, but have not been sustainably implemented. Crohn’s Colitis Care (CCCare), an IBD-specific electronic medical record used across Australasia to capture real-world data during routine care, has used these data to launch IBD-PERFECT, a clinician-led dashboard in September 2025. IBD-PERFECT enables benchmarking of key performance indicators (KPIs) and data completion across sites. Here we present initial results. Methods De-identified data from 20 sites flow into a clinical quality registry (CQR), from which KPI dashboards are fed. Dashboards were analysed in November 2025. The Clinical Cohort are those with ≥1 clinical assessment, while the Active Cohort are the most contemporaneous subset of the Clinical Cohort (reviewed within 14 months). Five KPIs were reported for the Active Cohort: current smoking, steroid or opiate use, clinically active disease (Crohn’s disease activity index ≥150, Harvey Bradshaw index ≥5, partial Mayo 2, or Simple Clinical Colitis Activity Index ≥5), and anaemia (haemoglobin 130 g/L men, 115 g/L women). A sixth KPI, eligibility for colorectal cancer surveillance, was calculated for those with primary sclerosing cholangitis or diagnosed ≥8 years earlier with colonic involvement. Data completion rates were calculated for each KPI. Aggregated results summarised using medians and interquartile ranges. Results 16,988 records were available, 10,178 (59.9%) in the Clinical and 6,506 (38.5%) in the Active Cohorts respectively; of whom 11,128 (65.5%) resided in Australia; 8,904 (52.4%) had Crohn’s disease and 7,171 (42.2%) ulcerative colitis. The median KPIs were: current smoking 1.3% (0.0–4.8), steroid use 1.1% (0.2–4.1), opiate use 0.6% (0.0–1.6), clinically active disease 7.9% (0.0–13.4), anaemia 0.1% (0.0–3.8), and surveillance eligibility 11.2% (1.8–23.4). Data completeness varied widely: smoking status 16.4% (2.5–43.4), opiate use 13.2% (2.3–44.2), disease activity indices 41.8% (22.3–71.0), haemoglobin 9.1% (0–42.9), and recent assessment 70.4% (48.6–82.2). Among those meeting surveillance criteria, 95.6% (88.5–100) lacked a documented colonoscopy within 3 years. While KPI rates appeared promising, wide variation in data completeness suggests that current figures may underestimate true rates and may not accurately reflect site-level performance, highlighting the need for improved data capture across all domains. Conclusion IBD-PERFECT provides a transparent, live platform for reviewing IBD care. Early results show variation in KPIs and documentation gaps. Improving CQR engagement will enable sites to use these insights to address care and recording gaps and drive quality improvement. Conflict of interest: Dr. Wu, Rodger: No conflict of interest Caquilpan, Victor: No conflict of interest Deschenes, Renee: No conflict of interest Wilson, William: No conflict of interest Su, Wai Kin: No conflict of interest Palmer, Lyle J: No conflict of interest Petch, Bill: No conflict of interest Jackman, Greg: No conflict of interest Langford, Simon: No conflict of interest Andrews, Jane Mary: Grant: The work I will present was funded via CCCure. CCCure’s funding sources include grants for research and payments for data reports from Pharma including AbbVie, J&J, Takeda, Celltrion, Falk, Ferring, BMS, Janssen, Pfizer, Sandoz Connor, Susan Jane: Grant: Research Support: Abbvie, Agency for Clinical Innovation, Amgen, BMS, Chiesi, Celltrion, DrFalk, Ferring, Janssen, Medical Research Future Fund, Pfizer, South Western Sydney Local Health District, Sydney Partnership for Health, Research and Enterprise, Takeda and The Leona M and Harry B Helmsley Charitable Trust Personal Fees: Ad Boards: Abbvie, Amgen, BMS, Celltrion, Eli Lilly, Ferring, GSK, Janssen, Organon, Pfizer, Takeda Speaker Fees: Abbvie, Cornerstones Health, Dr Falk, Ferring, Janssen, Pfizer, Sandoz, Sydney IBD School, Takeda Educational Support: DrFalk, Sandoz, Takeda
Wu et al. (Thu,) studied this question.